MedPath

Clinical Trial News

AI Revolutionizes Cancer Detection: Breakthroughs in Liquid Biopsies, Imaging, and Pathology

  • Advanced machine learning algorithms enable liquid biopsies for early lung cancer detection, potentially increasing annual lives saved from 600 to 12,000 in the United States through blood-based screening.
  • AI-powered imaging systems match radiologists' accuracy in breast cancer detection, demonstrating potential to reduce second reader workload by 88% in UK screening processes.
  • Deep neural networks in pathology achieve expert-level accuracy in tumor pattern classification, processing slides in under one minute while maintaining diagnostic quality comparable to practicing pathologists.

Cardiol Therapeutics' Cannabidiol Formulation Shows Cardioprotective Effects in Heart Failure Model

  • Study results demonstrate that Cardiol's pharmaceutical cannabidiol formulation significantly reduced cardiac hypertrophy and produced dose-dependent reductions in inflammation markers and fibrosis in a heart failure model.
  • The findings confirm the anti-inflammatory and anti-fibrotic properties of the company's cannabidiol formulation, supporting its potential as a cardioprotective therapy for heart conditions.
  • Cardiol Therapeutics is advancing plans for an international Phase 2 trial of its CardiolRx formulation in acute myocarditis, a leading cause of sudden cardiac death in young adults.

Long-term Benefits of Dose-dense Adjuvant Chemotherapy in Early Breast Cancer Patients

A study with a median follow-up of 15.8 years suggests that dose-dense (DD) chemotherapy may offer long-term benefits for high-risk early breast cancer patients, particularly those with hormone receptor-negative and HER2-positive tumors. The MIG-1 trial compared the efficacy and safety of DD versus standard-interval FEC chemotherapy, showing a trend towards improved outcomes with the DD approach.

Mycophenolate Mofetil Shows Promise in Phase II Osteosarcoma Trial

• A Phase II clinical trial is evaluating mycophenolate mofetil's efficacy and safety in patients with high-grade locally advanced or metastatic osteosarcoma. • The trial aims to determine progression-free survival at 16 weeks as the primary endpoint, with secondary endpoints including overall survival and safety parameters. • Mycophenolate mofetil, an immunosuppressant, has shown anticancer activity against osteosarcoma in preclinical studies, warranting further investigation in humans. • The study involves multiple centers in Thailand and includes adolescent and adult patients who have progressed after standard chemotherapy or are not candidates for it.

Five Key Strategies for Enhancing Patient-Centric Clinical Trials Amid Low Recruitment Rates

  • Clinical trials face significant challenges with less than 5% eligible participant enrollment and 30% dropout rates globally, highlighting the urgent need for patient-centric approaches.
  • Patient-reported outcomes (PROs) are gaining prominence, with 27% of studies on ClinicalTrials.gov incorporating patient perspective measurements to better assess treatment impact.
  • Modern clinical trials are embracing remote reporting technologies, rapid expense reimbursement, and lay result summaries to reduce participant burden and improve retention rates.

China Approves Clinical Trials for First COVID-19 Vaccine

  • China has approved clinical trials for its first vaccine against COVID-19, developed by a research group led by academician Chen Wei.
  • Pre-trial testing of the vaccine indicated it was both effective and safe, according to China Central Television.
  • Chen Wei and her team arrived in Wuhan on January 26 to investigate the coronavirus and develop methods to combat the epidemic.
  • The vaccine's approval marks a significant step in China's efforts to combat the COVID-19 pandemic, with clinical trials now underway.

Free Genetic Testing Initiative Accelerates Drug Development for Inherited Retinal Diseases

  • The Foundation Fighting Blindness's My Retina Tracker program offers free genetic testing and counseling for inherited retinal disease patients in the US, having enrolled over 6,000 participants since 2017.
  • ProQR Therapeutics becomes the first industry partner of the program, gaining access to crucial genotype/phenotype data to advance development of RNA-based therapies for specific genetic mutations.
  • The initiative aims to test 20,000 patients in coming years, helping overcome key challenges in rare disease drug development including patient identification and clinical trial optimization.

ApTOLL: Novel Aptamer-Based Therapy Shows Promise for Acute Ischemic Stroke Treatment

Neurology
  • aptaTargets is advancing ApTOLL, an innovative aptamer-based immune modulator that reduces brain damage in acute ischemic stroke by targeting TLR4 receptors.
  • Preclinical studies demonstrated ApTOLL's ability to reduce brain damage by up to 65% with an effective treatment window of 12 hours post-stroke onset.
  • Following successful Phase I trials in healthy volunteers (NCT04742062), the company is now conducting a Phase Ib/IIa clinical trial (APRIL study, NCT04734548) to establish proof-of-concept in stroke patients.

First in Human Clinical Trial of ApTOLL in Healthy Volunteers

NCT04742062CompletedPhase 1
aptaTargets S.L.
Posted 7/18/2019

Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

NCT04734548CompletedPhase 1
aptaTargets S.L.
Posted 10/28/2020

AMX0035 Slows Functional Decline in Amyotrophic Lateral Sclerosis

  • A new study reveals that AMX0035 significantly slows the progression of functional decline in patients with amyotrophic lateral sclerosis (ALS).
  • The trial demonstrated a statistically significant difference in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores between the AMX0035 and placebo groups.
  • AMX0035, a combination of sodium phenylbutyrate and taurursodiol, represents a promising therapeutic option for ALS, addressing a critical unmet need.
  • The findings support the potential of AMX0035 to improve the quality of life and extend survival for individuals affected by this devastating neurodegenerative disease.

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514CompletedPhase 2
Amylyx Pharmaceuticals Inc.
Posted 6/22/2017

Christie Hospital Launches Initiative to Boost Cancer Trial Access and Diversity

  • The Christie NHS Foundation Trust partners with Innovative Trials to enhance cancer clinical trial recruitment, focusing on improving access for patients in six key UK regions.
  • The initiative specifically targets underrepresented black, Asian, and minority ethnic communities, aiming to increase trial participation through culturally appropriate outreach materials.
  • A network of cancer centers will be established across the UK to enable local trial participation, addressing the fact that fewer than 50% of cancer patients recall discussing clinical trials post-diagnosis.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.